SLU-PP-332: ERR Agonist Exercise Mimetic Research, Muscle Fiber & Endurance

Written by NorthPeptide Research Team

For laboratory and research use only. Not for human consumption.

What Is SLU-PP-332?

SLU-PP-332 is a synthetic small molecule compound developed at Washington University in St. Louis — the “SLU” prefix in its name reflects this institutional origin. Unlike peptides, which are chains of amino acids, SLU-PP-332 is a low-molecular-weight organic compound designed to selectively activate estrogen-related receptors alpha and gamma (ERRα and ERRγ). It was first described in a 2023 publication in the Journal of Medicinal Chemistry and has since attracted significant research interest as a potential exercise mimetic — a compound that activates molecular pathways normally triggered by physical exercise.

It is important to clarify at the outset that SLU-PP-332 is not a peptide. It is a small molecule, placing it in the same general pharmacological category as conventional drugs rather than the peptide research compounds that make up the majority of exercise physiology reagents. Its inclusion in exercise mimetic research alongside compounds such as AICAR and MOTS-c reflects shared research goals — understanding and replicating the molecular benefits of exercise — rather than structural similarity.

The concept of an “exercise in a pill” has been a topic of scientific investigation for over a decade. Researchers have long observed that exercise produces a broad cascade of molecular changes — increased mitochondrial biogenesis, shifts in muscle fiber composition, improved oxidative metabolism, and enhanced fatty acid utilization — and have sought to identify the specific molecular switches responsible for these adaptations. SLU-PP-332 represents one of the more recent entries in this line of investigation, targeting a pathway distinct from earlier exercise mimetic candidates.

Mechanism of Action

SLU-PP-332 exerts its observed effects through direct agonism of the estrogen-related receptors (ERRs), specifically ERRα and ERRγ. Despite their name, ERRs do not bind estrogen and are not part of the classical estrogen signaling pathway. They are classified as orphan nuclear receptors — transcription factors that were identified by sequence homology to estrogen receptors but for which no natural endogenous ligand has been definitively established. ERRs regulate gene expression by binding to specific DNA response elements and recruiting transcriptional coactivators.

The ERR Pathway and Exercise

Under normal physiological conditions, ERRs are activated indirectly through interaction with the coactivator PGC-1α (peroxisome proliferator-activated receptor gamma coactivator 1-alpha). PGC-1α is widely recognized as a master regulator of mitochondrial biogenesis and is strongly upregulated during exercise. When PGC-1α levels rise in response to physical activity, it binds to ERRα and ERRγ, activating them and initiating a transcriptional program that drives several key metabolic adaptations:

• Mitochondrial biogenesis — ERR activation promotes the expression of genes involved in mitochondrial DNA replication, protein import, and organelle assembly, leading to an increase in mitochondrial density within cells.
• Oxidative phosphorylation — ERRs drive the expression of electron transport chain components and ATP synthase subunits, enhancing the capacity of cells to generate energy through aerobic metabolism.
• Fatty acid oxidation — ERR target genes include enzymes involved in beta-oxidation of fatty acids, increasing the ability of muscle and other tissues to utilize lipids as fuel substrates.
• Muscle fiber type regulation — ERR signaling, particularly through ERRγ, has been implicated in the specification and maintenance of Type I (slow-twitch, oxidative) muscle fibers, the fiber type associated with endurance capacity.

SLU-PP-332 bypasses the need for PGC-1α by directly binding to and activating ERRα and ERRγ. In preclinical models, this direct activation has been observed to engage the same downstream transcriptional program that exercise-induced PGC-1α would normally trigger, but without the requirement of physical activity as the initiating stimulus.

How SLU-PP-332 Differs from Other Exercise Mimetics

The exercise mimetic research field includes several compounds targeting different nodes of the exercise signaling network. Understanding where SLU-PP-332 fits within this landscape requires distinguishing between the pathways involved:

• AICAR (AMPK pathway) — AICAR is an adenosine analog that activates AMP-activated protein kinase (AMPK), a cellular energy sensor that responds to changes in the AMP/ATP ratio during exercise. AMPK activation promotes glucose uptake, fatty acid oxidation, and mitochondrial biogenesis through a pathway upstream of — but partially overlapping with — the PGC-1α/ERR axis. AICAR was the first compound widely studied as an exercise mimetic, with landmark research by Narkar et al. published in 2008.
• GW501516 (PPARδ pathway) — This compound activates peroxisome proliferator-activated receptor delta (PPARδ), another nuclear receptor involved in fatty acid metabolism and muscle fiber type regulation. PPARδ works in concert with the ERR pathway but through distinct transcriptional targets.
• SLU-PP-332 (ERR pathway) — By directly activating the ERR transcription factors, SLU-PP-332 engages a pathway that is downstream of PGC-1α but operates through a different entry point than AMPK activation. This means it may activate a complementary but not identical set of metabolic genes compared to AICAR.
• MOTS-c (mitochondrial signaling) — MOTS-c is a mitochondria-derived peptide that has been observed to activate AMPK and regulate cellular metabolism. It represents yet another entry point into exercise-related metabolic signaling, originating from the mitochondrial genome rather than nuclear receptor pathways.

These distinctions are significant because they suggest that different exercise mimetics may produce overlapping but non-identical metabolic effects, potentially activating different subsets of the broad transcriptional changes that occur during actual physical exercise.

Research Applications

The preclinical research on SLU-PP-332 has focused on several interconnected areas, all relating to its capacity to activate the ERR-mediated exercise transcriptional program.

Endurance and Running Capacity

The 2023 Washington University study published in the Journal of Medicinal Chemistry provided the foundational preclinical data for SLU-PP-332. In this study, mice treated with SLU-PP-332 demonstrated approximately 50% greater running endurance compared to vehicle-treated controls in treadmill exercise tests. This improvement in running capacity was observed without any accompanying exercise training protocol — the mice receiving SLU-PP-332 were sedentary yet performed at levels significantly exceeding those of untreated sedentary animals.

This finding paralleled earlier work with AICAR, which had similarly demonstrated improved endurance in sedentary mice through AMPK activation. However, the magnitude of the endurance effect observed with SLU-PP-332 and the distinct pathway involved (ERR vs. AMPK) represent a meaningful expansion of the exercise mimetic research field, suggesting that multiple independent molecular pathways can each contribute to endurance phenotypes.

Muscle Fiber Type Switching

One of the most notable findings from SLU-PP-332 research involves changes in skeletal muscle fiber composition. Mammalian skeletal muscle contains a spectrum of fiber types, broadly categorized as:

• Type I (slow-twitch, oxidative) — These fibers are rich in mitochondria, rely primarily on aerobic metabolism, are resistant to fatigue, and are the predominant fiber type in endurance-trained athletes. They appear darker in color due to high myoglobin content.
• Type IIa (fast-twitch, oxidative-glycolytic) — An intermediate fiber type with both aerobic and anaerobic capacity.
• Type IIx/IIb (fast-twitch, glycolytic) — These fibers generate high force but fatigue rapidly, relying predominantly on anaerobic glycolysis for energy production.

Endurance training in both animal models and humans is well documented to shift muscle fiber composition toward a greater proportion of Type I fibers — a process sometimes referred to as the “slow-twitch shift.” In the 2023 study, SLU-PP-332-treated mice exhibited a significant increase in the proportion of Type I oxidative muscle fibers compared to controls, mimicking the fiber type shift that normally requires weeks to months of endurance training. This finding is consistent with ERRγ’s known role in slow-twitch fiber specification and provides mechanistic support for the compound’s observed endurance effects.

Obesity and Metabolic Research

The Washington University research group also investigated SLU-PP-332 in the context of diet-induced obesity. Mice maintained on a high-fat diet and treated with SLU-PP-332 demonstrated resistance to weight gain compared to vehicle-treated controls on the same diet. This observation is consistent with the enhanced fatty acid oxidation capacity driven by ERR activation — if muscle and other tissues are metabolizing lipids more efficiently, less dietary fat would be expected to accumulate as adipose tissue.

The metabolic implications of ERR activation extend beyond simple energy expenditure. ERR-regulated genes are involved in multiple aspects of metabolic homeostasis, including glucose handling, lipid transport, and thermogenesis. The resistance to diet-induced obesity observed in SLU-PP-332-treated mice likely reflects the cumulative effect of enhanced oxidative metabolism across multiple tissue compartments rather than any single metabolic change.

Mitochondrial Function and Biogenesis

Given the central role of ERRs in mitochondrial gene regulation, SLU-PP-332 is of interest to researchers studying mitochondrial biology. ERR activation drives the expression of genes encoding mitochondrial respiratory chain complexes, mitochondrial transcription factors (TFAM), and proteins involved in mitochondrial dynamics (fusion and fission). In preclinical models, ERR agonism has been associated with increased mitochondrial density and enhanced respiratory capacity in skeletal muscle tissue.

This mitochondrial dimension of SLU-PP-332 research connects to broader investigations into conditions characterized by mitochondrial dysfunction, including age-related metabolic decline, sarcopenia, and metabolic syndrome. While SLU-PP-332 itself has not been directly studied in aging models to date, the ERR pathway it activates is a subject of active investigation in the biology of aging research community.

Metabolic Syndrome and Related Research

The convergence of SLU-PP-332’s observed effects — enhanced fatty acid oxidation, resistance to diet-induced obesity, improved oxidative muscle capacity, and increased mitochondrial function — positions it as a compound of interest in metabolic syndrome research. Metabolic syndrome, characterized by the clustering of insulin resistance, dyslipidemia, central obesity, and hypertension, is fundamentally a disorder of energy metabolism. The ERR pathway represents one of several molecular targets being investigated for its potential to address the metabolic dysregulation underlying this syndrome.

Preclinical Dosing Parameters

The following table summarizes the dosing parameters reported in published preclinical research on SLU-PP-332. These values reflect animal study protocols and cannot be directly extrapolated to other species. No human dosing data exists for this compound.

Parameter	Detail
Species	Mouse (C57BL/6)
Route of Administration	Intraperitoneal (IP) injection
Dose Range Studied	25–50 mg/kg body weight
Dosing Frequency	Once or twice daily
Study Duration	Up to several weeks (varies by protocol)
Vehicle	Standard pharmaceutical vehicle (DMSO-based formulation)
Key Outcome (Endurance)	~50% increase in treadmill running time vs. controls
Key Outcome (Fiber Type)	Increased proportion of Type I oxidative muscle fibers
Key Outcome (Obesity)	Resistance to weight gain on high-fat diet
Human Dosing Data	None — no human trials conducted

Important: Allometric scaling from mouse to human dosing is not straightforward. Body surface area normalization, differences in metabolic rate, bioavailability, and pharmacokinetic profiles between species all affect dose translation. The doses listed above are reported for reference to the published literature only.

Safety Profile

The safety data available for SLU-PP-332 is limited to preclinical observations. No human safety data exists, and no formal toxicology studies meeting Good Laboratory Practice (GLP) standards have been published for this compound.

Preclinical Observations

In the published mouse studies, SLU-PP-332 was reported to be well tolerated at the doses investigated. The Washington University researchers did not report significant adverse effects in treated animals during the study periods, and treated mice maintained normal behavior, grooming, and activity patterns outside of the structured exercise testing. Body weight was monitored as an experimental endpoint, and no unexpected weight loss or signs of toxicity were reported in the standard-diet groups.

Theoretical Safety Considerations

Several theoretical safety considerations arise from the mechanism of action of SLU-PP-332 and warrant discussion:

• ERR pathway specificity — While SLU-PP-332 was designed for selectivity toward ERRα and ERRγ, the broader nuclear receptor superfamily includes structurally related receptors. Off-target activation of other nuclear receptors could potentially produce unintended hormonal or metabolic effects. The degree of selectivity achieved by SLU-PP-332 at various concentrations is an important pharmacological question.
• Cardiac effects — ERRα and ERRγ are expressed at high levels in the heart, where they regulate cardiac energy metabolism. The heart is one of the most mitochondria-dense organs in the body, and ERR signaling plays a critical role in cardiac function. Whether systemic ERR agonism produces beneficial or adverse cardiac effects — or both, depending on context — remains an open research question. Exercise itself produces well-documented cardiac adaptations, and whether pharmacological ERR activation replicates these adaptations or produces a different cardiac response is unknown.
• Metabolic consequences of sustained activation — Exercise-induced ERR activation is transient, occurring during and shortly after physical activity before returning to baseline. Pharmacological ERR agonism with SLU-PP-332 could produce sustained pathway activation over longer periods. Whether chronic, uninterrupted ERR activation produces the same adaptive responses as the intermittent activation of exercise, or whether it leads to different biological outcomes, has not been determined.
• Reproductive considerations — ERRs are expressed in reproductive tissues and play roles in placental development and fertility in animal models. The effects of exogenous ERR agonism on reproductive biology have not been studied with SLU-PP-332.
• Long-term unknowns — The published research on SLU-PP-332 covers relatively short study durations. The effects of chronic, long-term ERR agonism on tissue homeostasis, cancer risk, immune function, and aging are entirely unknown. Given that ERRs regulate fundamental cellular processes including mitochondrial function and energy metabolism, the potential for unexpected long-term consequences cannot be excluded.

No Regulatory Safety Assessment

SLU-PP-332 has not undergone regulatory review by the FDA or any other health authority. No Investigational New Drug (IND) application has been filed, no Phase I safety trial has been conducted, and the compound does not appear on any regulatory agency’s list of approved or investigational substances. Researchers working with SLU-PP-332 should be aware that the safety profile of this compound is essentially uncharacterized in humans.

Comparison to Related Exercise Mimetic Compounds

Placing SLU-PP-332 in context with other exercise mimetics clarifies the distinct research questions each compound addresses:

Compound	Primary Target	Pathway	Key Preclinical Findings
SLU-PP-332	ERRα / ERRγ	Nuclear receptor / transcriptional	50% endurance increase, Type I fiber shift, obesity resistance
AICAR	AMPK	Cellular energy sensing	44% endurance increase (Narkar et al. 2008), enhanced fatty acid oxidation
MOTS-c	AMPK (mitochondria-derived)	Mitochondrial signaling peptide	Improved insulin sensitivity, exercise capacity, metabolic regulation
GW501516	PPARδ	Nuclear receptor / lipid metabolism	Endurance improvement, fatty acid oxidation, fiber type changes

Each of these compounds activates a different node in the complex signaling network that exercise engages. Real exercise simultaneously activates all of these pathways (and many others), which is one reason why no single exercise mimetic has fully replicated the breadth of exercise-induced adaptations. The identification of SLU-PP-332 as an ERR agonist adds another tool to the research toolkit for dissecting which specific pathways contribute to which specific exercise adaptations.

Current Research Limitations

A balanced assessment of SLU-PP-332 research requires forthright acknowledgment of its limitations:

• Very early-stage research — SLU-PP-332 was first published in 2023. The total body of published literature is small, limited primarily to the work of the Washington University group that developed the compound. Independent replication by other laboratories is essential before the findings can be considered robust.
• Mouse-only data — All published efficacy data comes from mouse models. While mice share many metabolic pathways with humans, interspecies differences in ERR biology, muscle physiology, and drug metabolism mean that mouse findings cannot be assumed to translate directly to human outcomes.
• No human data of any kind — Unlike BPC-157, which has at least limited human case reports, SLU-PP-332 has zero published human data. No pharmacokinetic, pharmacodynamic, safety, or efficacy data in humans exists.
• Short study durations — Published studies have employed relatively brief treatment periods. The effects of chronic exposure are unknown.
• Single research group — The majority of published SLU-PP-332 data originates from one institution. While this is normal for a newly developed compound, the scientific standard of independent replication has not yet been met.
• Oral bioavailability and formulation questions — As a small molecule, SLU-PP-332 was administered via injection in mouse studies. Oral bioavailability, metabolic stability, and optimal formulation for research use remain areas of ongoing investigation.

Summary

SLU-PP-332 is a small molecule ERRα/ERRγ agonist developed at Washington University in St. Louis that has generated significant interest as a novel exercise mimetic compound. By directly activating the estrogen-related receptors that are normally engaged by PGC-1α during physical exercise, SLU-PP-332 has been observed to trigger the transcriptional program associated with endurance training — including mitochondrial biogenesis, enhanced oxidative phosphorylation, increased fatty acid oxidation, and a shift toward Type I oxidative muscle fibers.

Preclinical data from the 2023 Journal of Medicinal Chemistry publication demonstrated that SLU-PP-332-treated mice achieved approximately 50% greater running endurance, exhibited increased oxidative muscle fibers, and showed resistance to diet-induced obesity. These findings, while preliminary, position SLU-PP-332 as a distinctive addition to the exercise mimetic research landscape, targeting the ERR pathway rather than the AMPK pathway engaged by AICAR or the mitochondrial signaling pathway associated with MOTS-c.

The research remains in its very early stages. All data comes from mouse models, no human studies have been conducted, no formal safety assessment exists, and independent replication of the primary findings is still needed. The ERR pathway itself, however, is well established in exercise physiology and metabolic research, providing a strong mechanistic foundation for continued investigation of compounds like SLU-PP-332 that can selectively engage this signaling axis.

For researchers interested in exercise mimetics, SLU-PP-332 represents an important new tool for understanding how the molecular benefits of exercise are mediated at the transcriptional level — and whether those benefits can be pharmacologically reproduced.

---

Summary of Key Research References

Study	Year	Type	Focus	Reference
Billon et al.	2023	In Vivo	Synthetic ERR agonist (SLU-PP-332) alleviates metabolic syndrome	PMC10801787
Kim et al.	2023	In Vivo	SLU-PP-332 induces ERR-dependent aerobic exercise response and enhances exercise capacity	PMC11584170
Garafalo et al.	2025	In Vivo	Targeting ERRs to counteract age-related muscle atrophy from inactivity	PMC12277287
Wang et al.	2023	In Vivo	ERR agonism reverses mitochondrial dysfunction and inflammation in aging kidney	PMC10734281
Patch et al.	2023	Pharmacology	Development of potent pan-ERR agonists, identification of SLU-PP-915	PMC10399613
Kim et al.	2025	In Vitro	In vitro metabolism and analytical characterization of SLU-PP-332	PMC12835572
Billon & Bhatt	2024	Review	Estrogen-related receptor signaling in skeletal muscle fitness	PMC11168301
Rangwala et al.	2010	In Vivo	ERR gamma as key regulator of muscle mitochondrial activity and oxidative capacity	PMC2903389

---

Research Disclaimer

For laboratory and research use only. Not for human consumption.

This article is intended solely as a summary of published scientific research on SLU-PP-332. It does not constitute medical advice, treatment recommendations, or an endorsement of SLU-PP-332 for any therapeutic purpose. SLU-PP-332 has not been approved by the FDA or any regulatory agency for human use. The research discussed herein is entirely preclinical (animal studies), and results from such studies may not translate to human outcomes. Researchers should consult relevant institutional review boards and regulatory guidelines before designing studies involving this compound.

NorthPeptide supplies research-grade compounds for legitimate scientific investigation. All products are sold strictly for laboratory and research purposes. https://northpeptide.com/products/slu-pp-332